Genome-wide association studies (GWAS) have identified numerous genetic variants associated with complex diseases, but mechanistic insights are impeded by a lack of understanding of how specific risk variants functionally contribute to the underlying pathogenesis 1 . It has been proposed that cis-acting effects of non-coding risk variants on gene expression are a major factor for phenotypic variation of complex traits and disease susceptibility. Recent genome-scale epigenetic studies have highlighted the enrichment of GWASidentified variants in regulatory DNA elements of disease-relevant cell types 2-6 . Furthermore, single nucleotide polymorphism (SNP)specific changes in transcription factor binding are correlated with heritable alterations in chromatin state and considered a major mediator of sequence-dependent regulation of gene expression 7-10 . Here we describe a novel strategy to functionally dissect the cisacting effect of genetic risk variants in regulatory elements on gene expression by combining genome-wide epigenetic information with clustered regularly-interspaced short palindromic repeats (CRISPR)/Cas9 genome editing in human pluripotent stem cells. By generating a genetically precisely controlled experimental system, we identify a common Parkinson's disease associated risk variant in a non-coding distal enhancer element that regulates the expression of α-synuclein (SNCA), a key gene implicated in the pathogenesis of Parkinson's disease. Our data suggest that the transcriptional deregulation of SNCA is associated with sequence-dependent binding of the brain-specific transcription factors EMX2 and NKX6-1. This work establishes an experimental paradigm to functionally connect genetic variation with disease-relevant phenotypes.
Genome-wide association studies (GWAS) have identified numerous genetic variants associated with complex diseases, but mechanistic insights are impeded by a lack of understanding of how specific risk variants functionally contribute to the underlying pathogenesis 1 . It has been proposed that cis-acting effects of non-coding risk variants on gene expression are a major factor for phenotypic variation of complex traits and disease susceptibility. Recent genome-scale epigenetic studies have highlighted the enrichment of GWASidentified variants in regulatory DNA elements of disease-relevant cell types 2-6 . Furthermore, single nucleotide polymorphism (SNP)specific changes in transcription factor binding are correlated with heritable alterations in chromatin state and considered a major mediator of sequence-dependent regulation of gene expression 7-10 . Here we describe a novel strategy to functionally dissect the cisacting effect of genetic risk variants in regulatory elements on gene expression by combining genome-wide epigenetic information with clustered regularly-interspaced short palindromic repeats (CRISPR)/Cas9 genome editing in human pluripotent stem cells. By generating a genetically precisely controlled experimental system, we identify a common Parkinson's disease associated risk variant in a non-coding distal enhancer element that regulates the expression of α-synuclein (SNCA), a key gene implicated in the pathogenesis of Parkinson's disease. Our data suggest that the transcriptional deregulation of SNCA is associated with sequence-dependent binding of the brain-specific transcription factors EMX2 and NKX6-1. This work establishes an experimental paradigm to functionally connect genetic variation with disease-relevant phenotypes.
Parkinson's disease is the second most common chronic progressive neurodegenerative disorder. The discovery of genes linked to rare Mendelian forms of Parkinson's disease has provided vital clues to the molecular and cellular pathogenesis of the disease 11 . However, over 90% of Parkinson's disease cases do not show Mendelian inheritance patterns, suggesting that sporadic, late-onset Parkinson's disease results from a complex interaction between genetic and environmental risk factors. While coding mutations and genomic multiplications of the SNCA gene cause familiar Parkinson's disease, GWAS have identified SNCA as one of the strongest risk loci associated with the sporadic form of the disease, suggesting a pivotal role in the pathogenesis of Parkinson's disease 12 . Genomic duplications of SNCA indicate that an increase by 50% in SNCA expression is sufficient to develop an autosomaldominant form of the disease, suggesting that Parkinson's disease associated risk variants might lead to a subtle increase in SNCA expression [13] [14] [15] . To analyse such small changes in gene expression despite considerable technical and biological heterogeneity of in vitro human pluripotent stem cell culture and differentiation systems, we conceived a novel experimental approach which allowed us to reliably quantify the consequences of targeted genetic modifications on transcription by analysing the cis-acting effects on allele-specific expression. Figure 1a , b illustrates how the heterozygous deletion or exchange of a candidate regulatory element through cis-regulatory effects on expression is predicted to modulate allele-specific gene expression when measured as the ratio between the modified and the non-targeted allele.
To analyse precisely the expression of two individual alleles in a single multiplex reaction, we adapted TaqMan SNP genotyping assays to quantitative reverse transcription polymerase chain reaction (qRT-PCR; Extended Data Fig. 1a ). A common SNP (rs356165 A/G, referred to as SNCA 'reporter SNP') was identified in the 3′ UTR of SNCA in two human embryonic stem (ES) cell lines and a common primer pair and allele-specific TaqMan probes conjugated with different fluorophores were used to distinguish between the two alleles (FAM to detect the A allele and VIC to detect the G allele). To validate this approach, we simulated allele-biased samples over a wide range of SNCA expression ratios by mixing cDNAs from two types of human induced pluripotent stem cell (iPS cell) derived neurons 16 that are homozygous for either the A or the G allele at the reporter SNP. Multiplex allele-specific qRT-PCR analysis robustly quantified the expression of each individual allele in the mixed samples ( Fig. 1c and Extended Data Fig. 1b ) with the relative allele-specific expression of the two alleles closely correlating with the expected ratio ( Fig. 1d ). Comparing neurons derived from isogenic cultures in parallel at different time points during terminal differentiation (Extended Data Fig. 2 ) revealed considerable differences in total SNCA expression ( Fig. 1e ). In contrast, allele-specific expression remained constant across all conditions ( Fig. 1f ). These data indicate that allele-specific TaqMan qRT-PCR analysis robustly allows detection of small effects on allele-specific expression, independent of cellular heterogeneity due to in vitro differentiation and maturation.
A recent analysis in post-mortem tissue from adult brain identified a significant enrichment of Parkinson's disease associated SNPs within distal enhancers 17 , consistent with the notion that GWAS variants in regulatory elements can be used to prioritize functional diseaserelevant risk alleles 18, 19 . To identify candidate risk variants in enhancers, we intersected Parkinson's disease associated SNPs in the SNCA locus (463 SNPs, P < 5 × 10 −8 provided by PDGene database) 12 with publicly available epigenetic data (NIH Roadmap Epigenomics Consortium; http://www.roadmapepigenomics.org) 20 . Ranking of all of Parkinson's disease associated SNPs in the SNCA locus based on cumulative overlap with enhancer-associated marks 3, 21, 22 such as H3K4me1, H3K27ac and DNase I hypersensitive sites (DHSs), revealed that the top seven risk variants were localized to two distal enhancer elements (intron-4 enhancer and 3′ UTR enhancer, Fig. 2a Table 1 ) with both displaying an active epigenetic signature in the substantia nigra and in human ES-cell-derived neurons (Extended Data Fig. 3b, d ). Because SNP-specific changes are thought to modify enhancer activity by altering transcription factor (TF) binding 7-10 , we analysed predicted TF binding by scanning for known binding sequence motifs comparing both alternative genotypes for each Parkinson's disease associated SNP. This analysis indicated that the risk LETTER RESEARCH variant rs356168 in the intron-4 enhancer is a TF binding hotspot with the highest number of predicted genotype-dependent differential binding of all of Parkinson's disease associated SNPs in the SNCA locus (Extended Data Fig. 3b , c; Supplementary Table 1 ).
To analyse the function of the intron-4 enhancer element, we deleted 500 bps of the epigenetically marked enhancer region containing the Parkinson's disease associated risk SNPs rs356168 and rs3756054 by CRISPR/Cas9-mediated genome editing ( Fig. 2b and Extended Data Figs 3b and 4a). We subsequently reinserted an allelic series of intron-4 enhancer elements harbouring all possible genotype combinations for rs356168 and rs3756054 into the enhancer-deleted cells ( Fig. 2b and Extended Data Fig. 4a ) to dissect sequence-specific effects of each risk variant. Southern blot analysis and genomic sequencing confirmed correct integration of the targeted enhancer elements in cis with the A (FAM) allele reporter SNP ( Fig. 2b and Extended Data Fig. 4 ). To analyse the effect of each enhancer genotype on SNCA expression, we differentiated between 2 and 4 individual clones targeted for each enhancer element into neural precursors or mixed neuronal cultures. Initial expression analysis for total SNCA and markers for neuronal and astrocytic differentiation showed no consistent differences between the genotypes (Extended Data Fig. 5a -c). In contrast, allele-specific qRT-PCR analysis revealed that neural precursors and neurons carrying the G allele at rs356168 showed a highly significant increase in expression of the A (FAM) reporter SNP compared with cells carrying the A allele at rs356168 and the homozygous enhancer deleted controls (Fig. 2c, d and Extended Data Fig. 5d -g). Because the inserted enhancer elements are in cis with the A (FAM) reporter SNP ( Fig. 2b ), we conclude that only insertion of enhancer sequences carrying the G allele at rs356168 results in increased expression of SNCA, whereas the A allele at this SNP has no effect compared with enhancer deleted controls. This effect was independent of the adjacent risk variant rs3756054, which has no considerable effect on allele-specific SNCA expression ( Fig. 2c, d and Extended Data Fig. 5d -g). Genotyping of the parental human ES cell line revealed that WIBR3 is heterozygous at SNP rs356168 with the A allele in cis with the A (FAM) reporter SNP and the G allele in cis with the G (VIC) reporter SNP (Extended Data Fig. 5h ). The homozygous deletion of the intron-4 enhancer resulted in decreased allele-specific expression of the G (VIC) allele (Extended Data Fig. 5i ) consistent with the observation that only the G allele at rs356168 significantly modifies the expression of the cis-regulated allele. Our results suggest that the intron-4 enhancer element regulates the transcription of SNCA in human neural precursor cells and neurons, and that the common SNP at rs356168 represents a functional risk variant, with the G allele causing increased expression. This is consistent with the GWAS data, which identify the non-active A allele at rs356168 as a protective allele with an odds ratio (OR) of 0.79 (0.76-0.81) 12 . In contrast, the Parkinson's disease associated SNP rs3756054 has no effect on SNCA expression suggesting that this variant is in linkage disequilibrium (LD) with the risk-modifying SNP.
To further support a functional effect of rs356168, we performed an expression quantitative trait loci (eQTL) analysis of total SNCA mRNA levels measured by qRT-PCR in 127 post-mortem frontal cortex samples (86 Parkinson's disease samples, 41 control samples). A significant increase in total SNCA levels (P = 0.031; linear regression analysis) was observed in carriers of the rs356168 risk allele (Extended Data Fig. 6b ). In comparison, only a modest and not significant increase (P = 0.33) in expression was observed for rs356229 (as proxy for top reported GWAS SNP 12 rs356182; R 2 = 0.62), indicating that rs356168 more precisely predicts SNCA expression levels.
To assess the extent to which rs356168 could explain the associations observed in the SNCA region in Parkinson's disease GWAS 12 , we completed a baseline and conditional analysis in 5 publicly available Parkinson's disease GWAS cohorts totalling 6,014 cases and 9,119 
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controls. The effect of the top reported GWAS SNP rs356182 was reduced 28% from an OR of 1.32 to 1.23 and the statistical significance was attenuated from a genome-wide significant P value of 1.1 × 10 −21 to 3.0 × 10 −6 (Extended Data Fig. 6a ). As expected, the independent 5′ region SNP rs7681154 which was revealed in the initial GWAS conditional analysis 12 continued to show a significant independent effect when conditioning on rs356168. Although this type of analysis cannot identify by itself functional risk variants, the results are consistent with the hypothesis that multiple functional variants with small size effects contribute to the overall association and heritability of the SNCA locus with sporadic Parkinson's disease (common disease-common variant hypothesis). The in vitro observed changes in allele-specific expression translate roughly to an increase of total SNCA expression of 1.06 times in neurons and 1.18 times in neural precursors. Given that a 1.5-fold increase in SNCA expression is sufficient to cause a familial autosomal-dominant form of Parkinson's disease, our data support the notion that a modest life-long increase of SNCA expression may represent the molecular basis of an increased risk to develop Parkinson's disease for carriers of the G allele.
Sequence-specific changes in chromatin state associated with differential enhancer activities, have been proposed as a mechanism for SNP-dependent cis-regulatory effects on gene expression [7] [8] [9] [10] . Chromatin immunoprecipitation (ChIP) followed by qRT-PCR (ChIP-qRT-PCR) for H3K4me1 and H3K27ac and ChIP-sequence (ChIP-seq) analysis for H3K27ac in neurons carrying all distinct genotypes indicated, that all intron-4 enhancer elements display a chromatin signature for an active enhancer (Extended Data Fig. 7 ). Normalization of intron-4 enhancer ChIPseq reads relative to the 3′ UTR enhancer of SNCA suggest a slight trend of increased H3K27ac read density in neurons carrying the G allele at rs356168 (Extended Data Fig. 7e ) consistent with sequencedependent changes of chromatin state and enhancer activity. However, considering the small SNP-dependent effect on transcription, it is difficult to distinguish between sequence-specific changes and technical variations resulting from in vitro differentiation associated variability.
Differential TF binding is considered a major mediator of sequence-specific effects of distal enhancers on gene regulation [7] [8] [9] [10] . We compiled a list of all TFs predicted to show SNP-specific binding at rs356168 by scanning the sequences of both alternative alleles for known binding motifs (Supplementary Table 2 ). We selected 10 candidate TFs (see Methods) and performed ChIP-qRT-PCR to identify candidates that specifically bind to the intron-4 enhancer element in in vitro differentiated neurons. This analysis identified binding of the brainexpressed TFs NKX6-1 and EMX2 ( Fig. 3a and Extended Data Fig. 8a ). Immunostaining confirmed the expression of EMX2 and NKX6-1 in human ES-cell-derived neurons and, to a lesser extent, in interspersed astrocytes (Extended Data Fig. 9f -j). Single-molecule mRNA fluoresence in situ hybridization (FISH) showed that more than 40% of the cultured cells were positive for one of the two TFs, while only a smaller fraction (around 20%) expressed both factors simultaneously (Extended Data Fig. 9a-e ). Importantly, electrophoretic mobility shift assay analysis (EMSA) revealed a clear SNP-dependent binding of EMX2 and NKX6-1 with preference for the protective lower SNCA expressing A allele at rs356168 (Fig. 3b , c and Extended Data Fig. 8b-e ). These results suggest a model in which the sequence-specific binding of EMX2 and NKX6-1 at a distal enhancer element represses enhancer activity and thus modulates SNCA expression ( Fig. 4 ). These data further suggest that the same enhancer elements may be regulated in distinct 
neuronal populations by different TFs, as it does not seem crucial that both proteins are expressed in the same cells. Indeed, the overexpression of EMX2 and NKX6-1 in terminally differentiated neurons, using a highly controlled doxycycline inducible system, resulted in significant downregulation of SNCA expression ( Fig. 3d ) further supporting this hypothesis. Our results are consistent with mouse models demonstrating a similar mechanism as repressors of enhancer function [23] [24] [25] .
Several genetic association studies identified a polymorphic microsatellite repeat region (SNCA-Rep1) 10 kb upstream of the transcription start site ( Fig. 2a ) associated with Parkinson's disease risk. These studies suggest that individuals homozygous for a shorter repeat region (Rep1-257 or Rep1-259) have a significant lower risk of developing Parkinson's disease than individuals carrying the longer forms (Rep1-261 or Rep1-263) 26 . Functional studies suggested an enhancerlike function based on the cis-regulatory correlation between the SNCA-Rep1 repeat length and SNCA expression 27, 28 . To test whether SNCA-Rep1 length influences SNCA expression in human neurons, we deleted the entire repeat region and subsequently inserted representative alleles for each of the 4 reported repeat length alleles 26 (Extended Data Fig. 10a ). Genomic sequencing, Southern blot analysis and fragment length analysis confirmed correct integration of the respective alleles (Extended Data Fig. 10b-d ). Multiple sub-clones of each of the SNCA-Rep1 alleles were differentiated into neurons and analysed for allele-specific SNCA expression. Athough individual clones varied considerably, no repeat length dependent effect of SNCA-Rep1 on SNCA expression was detected in two human ES cell lines (Extended Data Fig. 10e, f) . Moreover, the deletion of the entire repeat region thought to have the strongest effect an SNCA expression 27 did not significantly alter the allele-specific expression compared with the parental human ES cell lines or any of the other SNCA-Rep1 alleles. This result conflicts with the microsatellite repeat region exerting a cis-regulatory effect on of SNCA expression. It is possible that difficulties in controlling the experimental variables in neuroblastoma cells 28 or transgenic mice 27 affected the validity of the previous conclusions. As in vitro differentiated cells allow only for the analysis of early events, we cannot completely exclude an effect of the SNCA-Rep1 element at later time points or in combination with additional factors such as environmental stress.
The generation of patient-derived human iPS cells, which carry all pathogenic genetic alterations, is attractive for the study of diseases. However, significant biological heterogeneity due to differences in genetic background, variation in human iPS cell isolation and in vitro differentiation present a serious limitation for identifying a diseaserelevant phenotype in the culture dish 29 . This is particularly relevant for sporadic diseases likely displaying only subtle in vitro phenotypes. Here we describe an alternative experimental approach to identify functional risk variants based on three recent innovations in genetics and molecular biology: (i) the prioritization of GWAS-identified risk variants in regulatory elements such as distal enhancers annotated based on genome-scale epigenetic data; (ii) the generation of genetically controlled isogenic pluripotent stem cell lines in which specific disease-associated genetic variants are the sole modified experimental variable using efficient gene-editing technologies such as the CRISPR/Cas9 system 30 ; and (iii) the analysis of cis-acting effects of candidate variants on allele-specific gene expression through deletion or exchange of disease-associated regulatory elements. This approach eliminates the effect of system inherent variability such as in vitro differentiation and results in an internally controlled experimental system, which allows robust and reproducible identification of cis-acting sequence-specific effects on gene regulation. Importantly, the experimental paradigm established here is not only relevant for Parkinson's disease, but is generally applicable for mechanistic studies of the molecular consequences of risk alleles associated with other diseases.
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METHODS
Human ES cell and human iPS cell culture. Human ES cell and human iPS cell culture conditions have been described previously 30 . Human iPS cell 16 and human ES cell lines WIBR3 (Whitehead Institute Center for Human Stem Cell Research, Cambridge, MA) 31 and BGO1 (NIH Code: BG01; BresaGen, Athens, GA) were maintained on mitomycin C-inactivated mouse embryonic fibroblast (MEF) feeder layers in human ES cell medium (DMEM/F12 (Invitrogen) supplemented with 15% fetal bovine serum (FBS) (Hyclone), 5% KnockOut Serum Replacement (Invitrogen), 1 mM glutamine (Invitrogen), 1% nonessential amino acids (Invitrogen), 0.1 mM β -mercaptoethanol (Sigma) and 4 ng ml −1 FGF2 (R&D systems)). Cultures were passaged every 5 to 7 days either manually or enzymatically with collagenase type IV (Invitrogen; 1.5 mg ml −1 ). All experiments in this study were performed in a sub-clone of WIBR3 and BGO1 with a targeted inframe insertion of EGFP into the NURR1 locus (data not shown) which should not influence the results reported here and will be described in detail in a separate publication. The identities of all parental human ES and human iPS cell lines were confirmed by DNA fingerprinting and all cell lines were regularly tested to exclude mycoplasma contaminations using a PCR based assay. NPC culture and terminal differentiation. Differentiation into neural precursor cells (NPCs) and terminal differentiated neurons was performed according to previously described protocols with slight modifications 16, 30, 32 . All cell lines for each individual experiments were differentiated in parallel to further reduce experimental variability. Briefly, human pluripotent stem cell colonies were harvested using 1.5 mg ml −1 collagenase type IV (Invitrogen), separated from the MEF feeder cells by gravity, gently triturated and cultured for 8 days in non-adherent suspension culture dishes (Corning) in EB medium (DMEM (Invitrogen) supplemented with 20% KnockOut Serum Replacement (Invitrogen), 0.5 mM glutamine (Invitrogen), 1% nonessential amino acids (Invitrogen), 0.1 mM β -mercaptoethanol (Sigma)) supplemented with 50 ng ml −1 human recombinant Noggin (Peprotech) and 1,000 nM dorsomorphin (Stemgent). Subsequently human EBs were plated onto poly-l-ornithine (15 μ g ml −1 , Sigma), laminin (1 μ g ml −1 Sigma), fibronectin (2 μ g ml −1 Sigma) coated tissue culture dishes in N2 medium 33 supplemented with 50 ng ml −1 human recombinant Noggin (Peprotech), 1,000 nM dorsomorphin (Stemgent) and FGF2 (20 ng ml −1 , R&D systems). After 8 days, neural rosettebearing EBs were cut out by microdissection, dissociated using 0.05% trypsin/ EDTA solution (Invitrogen) and subsequently expanded on poly-l-ornithine, laminin and fibronectin coated cell culture dishes a density of 5 × 10 5 cells per cm 2 in N2 medium supplemented with FGF2 (20 ng ml −1 , R&D systems). Proliferating NPCs were passaged 2 to 4 times before induction of terminal differentiation into neurons by growth factor withdrawal in N2 medium supplemented with ascorbic acid (Sigma). Differentiated neurons were used for analysis between day 25 and 31 day after differentiation. After terminal differentiation, the cultures consist primarily of excitatory glutamatergic neurons and astrocytes with few other detectable cell types such as dopaminergic neurons (Extended Data Fig. 2 ). In addition neural precursor cells were also included in in gene expression analysis due to the robust expression of SNCA at this developmental stage. CRISPR/Cas9 gRNA and donor vector design. To generate gRNA expression vectors, which express a fluorescent marker protein for FACS sorting in addition to Cas9 and the gRNA, we modified the pX330 gRNA expression vector 34 by insertion of either a CMV-EGFP-pA (pX330-EGFP), CMV-YFP-pA (pX330-YFP), CMV-mCherry-pA (pX330-mCherry) or CMV-BFP-pA (pX330-BFP) into the Not1 and Sbf1 restriction sites. Annealed oligonucleotides for each targeting site ( Supplementary Table 3a ) were ligated in to the BbsI restriction site as described previously 35 . Donor plasmids were generated by inserting a genomic PCR-amplified fragment ( Supplementary Table 3b , 1,834 bp for the intron-4 enhancer and 2,333 bp for SNCA-Rep1) into the pCR2.1-TOPO-TA cloning vector (Life technologies) according to the provider's instructions. Donor plasmids for intron-4 enhancer targeting to insert the four genotypes ( Supplementary  Table 3b ) were generated by replacing the wild-type sequence between the Mfe1 and Sty1 restriction sites with a synthetized gene fragment (gBlock, Integrated DNA technologies, Iowa). Donor plasmids for SNCA-Rep1 targeting to insert the four SNCA-Rep1 genotypes ( Supplementary Table 3b ) were generated by replacing the wild-type sequence between the Mfe1 and Stu1 restriction sites with corresponding SNCA-Rep1 fragments selected from a sub-cloned haplotypes derived from a collection of human cell lines. CRISPR/Cas9-mediated genome editing of human ES cells. CRISPR/ Cas9-mediated genome editing of human ES cells was performed as described previously 30, 36 . Human ES cells or the respective targeted sub-clones were cultured in Rho-associated protein kinase (ROCK)-inhibitor (10 μ M, Stemgent; Y-27632) 24 h before electroporation. Cells were harvested using 0.05% trypsin/EDTA solution (Invitrogen) and resuspended in phosphate buffered saline (PBS). For genomic deletions, 1 × 10 7 cells were electroporated with 22.5 μ g of each gRNA expression vector ( Supplementary Table 3a ). For insertion of SNCA-Rep1 or intron-4 enhancer haplotypes, 1 × 10 7 cells were electroporated with 15 μ g gRNA expression vector and 30 μ g of the respective donor vector ( Supplementary Table 3a, b ). Cells were maintained on MEF feeder layers for 72 h in the presence of ROCK inhibitor followed by FACS sorting (FACS-Aria; BD-Biosciences) of a single-cell suspension for cells expressing the respective fluorescent marker proteins ( Supplementary  Table 3a ) and subsequently plated at a low density in human ES cell medium supplemented with ROCK inhibitor for the first 24 h. Individual colonies were picked and expanded 10 to 14 days after electroporation. Correctly targeted clones were subsequently identified by genomic sequencing with primers outside of the targeting region ( Supplementary Table 3c ), by Southern blot analysis and for the SNCA-Rep1 targeting by fragment length analysis. All targeted and maintained cell lines used for subsequent experiments are summarized in Supplementary Table 3g . Southern blotting. Genomic DNA was separated on a 0.7% agarose gel after restriction digests with the appropriate enzymes, transferred to a nylon membrane (Amersham) and hybridized with 32 P random primer (Agilent)-labelled probes. Fragment length analysis. Fragment length analysis for SNCA-Rep1 was performed as described previously 26 using the Type-it Microsatellite PCR Kit (Qiagen) according to providers instruction using a SNCA-Rep1-forward and 5′ -FAM (Fluorescein) labelled SNCA-Rep-1 reverse Primer ( Supplementary Table 3c ). Fragment length along with an appropriate standard was determined using a 3730xl DNA analyser (Applied Biosystems) and analysed with Peak Scanner software 2 (Applied Biosystems). Genomic sequencing-based phase-reconstruction. Genomic DNA from wildtype WIBR3 and targeted clones was amplified using PlatinumTaq DNA polymerase (Life Technologies) and primer pairs indicated in Supplementary Table 3d . PCR products were sub-cloned using TOPO XL-PCR cloning kit (Life Technologies) according to the providers' instructions and between 6 and 10 individual clones were submitted for sequencing. The phase between intron-4 enhancer SNPs (rs356168 and rs3756045) and the reporter SNP (rs356165) was manually determined based on the genotype of linked heterozygous SNPs in the respective fragments ( Supplementary Table 3d ). Allele-specific quantitative reverse transcription polymerase chain reaction (qRT-PCR). RNA was isolated using the RNeasy Mini Kit (Qiagen) including on-column DNase digest to remove genomic DNA. Reverse transcription was performed on 0.5-1 μ g of total RNA using oligo dT priming and SuperScript III First-Strand Synthesis SuperMix (Life technologies) at 50 °C according to the provider's instructions. The SNP genotyping TaqMan assays for allele-specific SNCA probes and TaqMan gene expression analysis assay targeting the 3′ UTR of SNCA and GAPDH were custom designed or provided by the manufacturer ( Supplementary Table 3c ; Applied Biosystems). All samples were performed in technical triplicates in a 384-well plate format on a 7900HT Fast Real-Time PCR system (Applied Biosystems) using Taqman Universal Master MIX II with UNG (Applied Biosystems) according to the manufacturers' instructions. Sequential dilution samples from neurons derived from human iPS cells that are homozygous for either the A allele (IPSC-PDA derived from AG20443) 16 or G allele (IPSC-PDB derived from AG20442) 16 at the reporter SNP (rs357165) were included to determine primer efficiency for each experiment separately. Relative quantification of allele-specific expression of SNCA was calculated using the Pfaffl method 37 that incorporates primer efficiencies, using total SNCA expression (3′ UTR-SNCA TaqMan assay) as the reference gene and dependent on experimental design, the average of either wild-type or enhancer deleted cells (WIBR3 Δ E4/Δ E4) as calibrator. Allele-specific SNCA expression proportions were calculated relative to calibrator samples which were set to 0.5. All statistical analyses were calculated using GraphPad Prism 6 for Mac. No statistical methods were used to predetermine sample size. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. Significant differences between genotypes were calculated using oneway or two-way ANOVA followed by Tukey's multiple comparison test based on allele-specific expression from 3 biological replicates (representing the mean of 3 technical replicates) for each of the individual subclones as indicated in the figure legends. For statistical analysis all biological replicates of individual clones were combined according to genotypes. Equal variances between genotypes were tested using a Brown-Forsythe test. In addition the observed effects were confirmed using the non-parametric Kruskal-Wallis test followed by Dunn's multiple comparisons test. The allele-specific expression data and the detailed statistical analysis corresponding to data displayed in Fig. 2c, d and Extended Data Fig. 5d -g are provided as Source Data for Fig. 2 and Source Data for Extended Data Fig. 5 . Reverse transcription of total RNA and real-time PCR. RNA was isolated using the RNeasy Mini Kit (Qiagen) including on-column DNase digest to remove genomic DNA. Reverse transcription was performed on 0.5-1 μ g of total RNA using oligo dT priming and SuperScript III First-Strand Synthesis SuperMix (Life technologies) at 50 °C according to provider's instructions. All PCR reactions were performed in a 384-well plate format on a 7A900HT Fast Real-Time PCR system (Applied Biosystems) using either Taqman Universal Master MIX II with UNG (Applied Biosystems) or Platinum SYBR green qPCR SuperMIX-UDG with ROX (Invitrogen) according to the manufacturers' instructions using primer as summarized in Supplementary Table 3c . Relative quantification of gene expression was calculated using the 2-Δ Δ C t method using GAPDH (Taqman) or 60S acidic ribosomal protein P0 (RPLP0 for SYBR green) as reference and untreated control samples (as specified in the figure legends) as calibrator. All statistical analyses were calculated using GraphPad Prism 6 for Mac. Detailed statistical information is included in the corresponding figure legends. No statistical methods were used to predetermine sample size. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. Chromatin immunoprecipitation (ChIP-qRT-PCR and ChIP-seq). ChIP-qRT-PCR and ChIP-seq was performed as described previously 38 . 10 7 cells per ChIP assay were cross-linked for 10 min at room temperature by the addition of one-tenth of the volume of 11% formaldehyde solution (11% formaldehyde, 50 mM HEPES pH 7.3, 100 mM NaCl, 1 mM EDTA pH 8.0, 0.5 mM EGTA pH 8.0) to the growth media followed by quenching with 100 mM glycine. Cells were washed twice with PBS, then the supernatant was aspirated and the cell pellet was flash frozen in liquid nitrogen. 20 μ l of magnetic Dynabeads (Sigma) were blocked with 0.5% BSA (w/v) in PBS. Magnetic beads were bound with 2 ug of antibody indicated in Supplementary Table 3e . Cross-linked cells were lysed with lysis buffer (50 mM HEPES pH 7.3, 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP-40, and 0.25% Triton X-100) and resuspended and sonicated in sonication buffer (50 mM Tris-HCl (pH 7.5), 140 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% Na-deoxycholate, 0.1% SDS). Cells were sonicated at 4 °C with a Bioruptor (Diagenode) at high power for 25 cycles for 30 s with 30 s between cycles. Sonicated lysates were cleared and incubated overnight at 4 °C with magnetic beads bound with antibody ( Supplementary Table 3e ) to enrich for DNA fragments bound by the indicated TF. Beads were washed two times with sonication buffer, one time with sonication buffer with 500 mM NaCl, one time with LiCl wash buffer (20 mM Tris pH 8.0, 1 mM EDTA, 250 mM LiCl, 0.5% NP-40, 0.5% Na-deoxycholate) and one time with TE with 50 mM NaCl. DNA was eluted in elution buffer (50 mM Tris-HCL pH 8.0, 10 mM EDTA, 1% SDS). Cross-links were reversed overnight. RNA and protein were digested using RNase A and Proteinase K, respectively and DNA was purified with phenol chloroform extraction and ethanol precipitation. Target-specific binding was analysed by quantitative RT-PCR on a 7900HT Fast Real-Time PCR system (Applied Biosystems) using with Platinum SYBR green pPCR SuperMIX-UDG with ROX (Invitrogen) using primers targeting either the intron-4 enhancer or an adjacent negative control in the SNCA locus or a unrelated negative control region on chromosome 8. Target-specific binding of the intron-4 enhancer or control region for each antibody was calculated as fold-enrichment over IgG-Isotype control ChIP. Similarly processed H3K27ac samples postpurification were used to prepare Illumina multiplex sequencing libraries. Libraries for Illumina sequencing were prepared following the Illumina TruSeq DNA Sample Preparation v2 kit protocol with the following exceptions. After end-repair and A-tailing, immunoprecipitated DNA (~ 10-50 ng) or whole cell extract DNA (50 ng) was ligated to a 1:50 dilution of Illumina Adaptor Oligo Mix assigning one of 24 unique indexes in the kit to each sample. Following ligation, libraries were amplified by 18 cycles of PCR using the HiFi NGS Library Amplification kit from KAPA Biosystems. Amplified libraries were then size-selected using a 2% gel cassette in the Pippin Prep system from Sage Science set to capture fragments between 300 and 700 bp. Libraries were quantified by qRT-PCR using the KAPA Biosystems Illumina Library Quantification kit according to kit protocols. Libraries with distinct TruSeq indexes were multiplexed by mixing at equimolar ratios and running together in a lane on the Illumina HiSeq 2500 for 40 bases in single read mode. Reads were de-multiplexed by their adaptor ID and aligned to the hg19 version of the human reference genome using Bowtie 1.1.1 with parameters -wrapper basic-0 -p 4 -k 2 -m 2 -sam and -l 40 (ref. 39 ). Parkinson's disease associated SNP prioritization based on overlap with epigenetic enhancer marks. We prioritized Parkinson's disease associated highconfidence enhancer elements as being broadly active throughout the brain based on the observation that Parkinson's disease associated pathology is not exclusively localized to the substantia nigra, but rather affects a wide variety of neuronal cell types [40] [41] [42] . DHSs data sets were included because the comparison between fetal and adult DHSs harbouring disease-associated GWAS variants suggests that the vast majority of these DHSs are already established in fetal tissues 3 . Mapped read files of H3K27ac ChIP-seq, H3K4me1 ChIP-seq, H3K4me3 ChIP-seq, and DHSs created as part of the Human Epigenome Roadmap Project were downloaded from Gene Expression Omnibus (GEO), and the samples used are summarized in Supplementary Table 3f . These data sets were used to prioritize Parkinson's disease associated SNPs by their presence in putative regulatory regions in human brain samples (Supplementary Table 1 ). Regions of enrichment in H3K27ac signal, H3K4me1 signal, H3K4me3, or DHSs in human samples were calculated using MACS 1.4.2 (ref. 43) using parameters -p 1e-9,-keep-dup = auto, and -g hs with no control library. For each SNP in the SNCA locus from hg19 chromosome 4 position 90453241 (rs67262058) to position 91220981 (rs17016715) (463 SNPs, P < 5 × 10 −8 provided by PDGene database 12, 44 ), the number of data sets with a region enriched in H3K4me1, H3K27ac, or DNase hypersensitivity contacting or containing the SNP were summed. SNPs were ranked by this sum. SNPs in the promoter region of SNCA were excluded based the overlap of H3K4me3 peaks, a histone modification that is enriched at the transcription start site (TSS) of actively expressed genes identified in each ChIP-seq sample. Display of ChIP-seq and DHSs signal. WIG files for display of read pileup for ChIP-seq and DHSs performed by the Epigenome Roadmap Consortium were downloaded from GEO, and these samples are compiled in Supplementary Table 3f . For new data sets generated for this manuscript we created WIG files representing read counts in 50 bp bins using macs 1.4 (ref. 43 ) with parameters -w -Sspace = 50 -nomodel -shiftsize -p 1e-9 -keep-dup = 1. Samples were normalized to reads in each bin per million mapped reads to enable cross-sample comparisons. This was achieved by dividing the value in each bin by the millions of mapped reads per sample and conversion to TDF files for display in IGV using igvtools.
Relative enhancer ChIP-seq signal calculation in CRISPR/Cas9 targeted cells.
For Extended Data Fig. 7e , the signal of H3K27ac ChIP-seq at the enhancer containing the variable allele was calculated in five cell lines with and without deletion or additional alteration of the underlying sequence. The SNP-containing enhancer was defined as chr4: 90673430-90675431, and the 3′ UTR enhancer used for normalization was defined as chr4: 90629326-90631326. Aligned reads in these windows were counted using intersectBed 45 Because visual inspection indicated that the 3′ UTR enhancer was consistent in signal, and because no genetic perturbation to this region was performed, we used the read count in this region to normalize across samples for comparison. The ratio of number of reads in the variable SNP-containing enhancer divided by reads in the 3′ UTR enhancer is reported. Conditional GWAS meta-analysis. Genomewide SNP data was obtained for 5 cohorts (GenePD/PROGENI, phs000126.v1.p1; NINDS, phs000089.v3.p2; NGRC, phs000196.v2.p1; APDGC, phs000394.v1.p1; WTCCC, EGAS00000000034). Each cohort was imputed to the 1000G phase 3 reference genome using Minimac 46, 47 . Baseline and conditional association of the GWAS hits reported by Nalls et al. to Parkinson's disease risk was performed using SAS for each of the 5 cohorts as describe previously 12 . Association results for each cohort were combined using fixed effects models with standard error weighting implemented in METAL 48 . eQTL study in Parkinson's disease and control postmortem frontal cortex. The SNCA gene expression data set and analysis methods used here have been described previously 49 . In brief, SNCA expression levels were assayed from 165 samples using quantitative real-time polymerase chain reaction. The relative standard curve method was used to transform the C t values into quantity units. The base 10 logarithm of the SNCA expression values was used for all analyses, to ensure the normal distribution of data required by the statistical tests performed. SNP genotyping was performed as part of the US PD-GWAS Consortium metaanalysis replication sample 50 . As described in the consortium study, the samples were genotyped at the Center for Inherited Disease Research (CIDR) using a custom Illumina genotyping array of 768 SNPs. Because the tested SNP data set did not include the top reported Parkinson's disease associated SNP rs356182 in the SNCA locus, we included rs356229 as proxy for this SNP (R 2 = 0.62) in our analysis. After quality control, genotyping and expression data was available for 86 cases and 41 controls for eQTL analysis. Expression models were analysed including adjustment for disease status, sex, pH, age at death, as well as for the interaction between PMI and disease status and significance was assessed using a one-sided test based on the a priori hypothesis of an association of the G allele at rs356168 with increased SNCA expression. TF binding site prediction. We extracted the nucleotide sequence for the region chr4: 90450000-91221000, that includes the SNCA locus, using the hg19 genome release, and made an alternative 'minor allele' version of the sequence that contains all Parkinson's disease associated SNP-derived minor alleles from position 90453241 (rs67262058) to position 91220981 (rs17016715). Any minor allele SNPs less than 50 nt apart were included in separate sequence files. This way we could evaluate the effect of the minor allele within the reference wild-type sequence context. We predicted all TF binding sites for the reference sequence and the sequences containing minor alleles using match, the matrix library "matrix.dat" from the TRANSFAC Release 2014.1, and the matrix profile minSUM_good.prf. We summarized the TFs predicted to bind the wild-type and minor allele sequences with the BEDTools suite and a custom perl script. To select candidate TFs, the list of differential binding matrices was filtered for TFs that (i) show high expression LETTER RESEARCH levels in the top 25th percentile of all transcripts based on RNA-sequencing data derived from in vitro differentiated neurons (data not shown), (ii) show robust expression in disease-relevant brain areas based on data from the Allen Brain Atlas 51 and (iii) display gene ontology (GO) terms related to brain function 52, 53 . Electrophoretic mobility shift assay (EMSA). HEK-293 cells transiently transfect using X-tremeGene 9 (Roche) with plasmids expressing either EMX2-Myc-DDK or NKX6-1-Myc-DDK (pCMV6-Entry, OriGene) or wild-type cells were used to prepare nuclear extracts according to standard protocols. Gel-shift assay was performed with the LightShift Chemiluminescent EMSA Kit (Thermo Scientific) according to manufacturer's instructions. For the competition experiments, 5′ -biotin-labelled oligonucleotides carrying either the A allele or G allele at rs356168 spanning 60 bp around the SNP and corresponding unlabelled competitor oligonucleotides (all Integrated DNA Technologies) were included in the binding reaction to determine the allele-specific binding of EMX2 or NKX6-1 respectively. Binding reactions were separated using precast 6% DNA retardation gels or 4-20% TBE gels (Life Technologies) in 0.5X TBE, electrophoretically transferred to Biodyne B nylon membranes (Thermo Scientific) and detected by chemiluminescence.
Doxycycline-inducible expression of EGFP, EMX2 and NKX6-1 in human ES-cell-derived neurons.
Myc-DDK-tagged human cDNAs for EMX2 and NKX6-1 (derived from pCMV6-Entry Clones, OriGene) were subcloned into FUW-Tet-O-EGFP vectors to generate the FUW-Tet-O-EMX2 and FUW-Tet-O-NKX6-1 doxycycline-responsive lentiviral vectors. VSV-G coated lentiviruses were generated in 293T cells as described previously 54 . Briefly, 293T cells were transfected with a mixture of viral plasmid and packaging constructs expressing the viral packaging functions and the VSV-G protein. Culture medium was changed 12 h post-transfection and virus-containing supernatant was collected 60-72 h post transfection. Viral supernatant was filtered through a 0.45 μ m filter. Virus-containing supernatants were concentrated by ultracentrifugation. All experiments were performed in 2 individual clones derived from WIBR3 cells, in which the constitutive active reverse tetracycline transactivator (AAVSIneo-M2rtTA) was targeted into the AAVSI 'safe harbour' locus as described previously 36, 55 . In vitro differentiated neural precursors derived from these cells lines were transduced with various amounts of concentrated virus for 24 h. Only cultures that expressed the transgenes in more than 75% of the cells (as determined by GFP fluorescence and immunostaining for expression of the DDK-tag) were used for further experiments. Transduced cells were terminally differentiated for 21 days. Transgene expression was induced in 24-well plates by supplementing the medium with doxycycline at a final concentration of 2 μ g ml −1 . Doxycyclineinduced transgene expressing samples and untreated isogenic controls were lysed 72 h after doxycycline and subsequently analysed by qRT-PCR. Single molecule mRNA flouresence in situ hybridization (FISH). We performed RNA FISH as outlined previously [56] [57] [58] . The neuronal cultures (differentiation day 21) were washed with HBSS, detached and dissociated into single cells with HBSS and subsequently fixed with paraformaldehyde at a final concentration of 4%. The cells were incubated for 10 min while rotating to avoid clumping of cells. After 10 min the cells were spun down for 6 min at 1,000 r.p.m. To permeablize the cells, the cells were placed in 70% ethanol overnight. The next day the cells were attached to chambered cover slides (Nunc Lab-Tek) coated with poly-l-lysine. The 20 nt probes for EMX2 and NKX6-1 were manually designed and ordered through Biosearch Technologies, coupled with either Cy5-flurophore or Alexa594fluorophore (Invitrogen), respectively, and hybridized with standard FISH hybridization buffer containing 25% formamide. For hybridization conditions 75 ng probes per μ l of hybridization buffer were used. The probes were hybridized for 16 h at 30 °C followed by two wash steps with wash buffer containing 25% formamide and 2× SSC. The cells were counterstained with Hoechst 33342. During imaging the cells were kept in a solution containing PBS, glucose, catalase and Trolox to avoid bleaching of fluorophores. All images were taken with a Nikon Ti-E inverted fluorescence microscope equipped with a 100× oil-immersion objective and a Photometrics Pixis 1024 CCD camera using MetaMorph software (Molecular Devices, Downington, PA). A total of 100 cells were counted for quantification. Cells that seemed fragmented or had an excessive amount of background were excluded. All cells with more than two transcripts for either NXK6-1 or EMX2 were counted as positive for the respective transcript. Immunocytochemistry. Cells were fixed with 4% (w/v) paraformaldehyde in PBS for 20 min at room temperature, and rinsed with PBS. Following membrane permeabilization with PBS containing 0.2% Triton, cells were blocked with 5% normal donkey serum and stained with indicated primary antibodies ( Supplementary  Table 3e ) overnight at 4 °C. Immunostainings were visualized by appropriate secondary antibodies conjugated with Alexa 488, 568, 594, 633 (Life Technologies), followed by counter-staining with DAPI. Table summarizing intron-4 enhancer deletions and insertions of indicated haplotypes in WIBR3 human ES cells. Correct targeting was determined by Southern blot analysis and genomic sequencing. Cell lines with targeted enhancer elements confirmed to be in cis with A (FAM) reporter SNP (determined by genomic sequencing-based phase-reconstruction) were maintained for subsequent analysis (compare Fig. 2b ).
LETTER RESEARCH
